Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Targeted Delivery of CD34 Aptamer-Coupled Tocilizumab Microspheres for Effective Treatment of Thyroid-Associated Ophthalmopathy

Luo Y., Yin J., Cao J., Xie B., Zhang F., Ouyang S.

Animal Study on Chronic Wound, Autoimmune Research, published in Invest Ophthalmol Vis Sci (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Invest Ophthalmol Vis Sci (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40853309
PMCID
PMC12380113
DOI
10.1167/iovs.66.11.57
Citations
1

Abstract (original English)

Purpose Thyroid-associated ophthalmopathy (TAO) is a debilitating autoimmune disorder linked to Graves' disease (GD) that is characterized by inflammation and remodeling of orbital tissues. This study focuses on the use of poly(lactic-co-glycolic) acid (PLGA)-based microspheres (MS) coupled with CD34-specific aptamers to enhance the targeted delivery of Tocilizumab (Toc), an IL-6 receptor monoclonal antibody, to CD34+ orbital fibroblasts, which is a critical cell type implicated in TAO. Methods The flow cytometry and aptamer-mediated pull-down assays were applied to detect the affinity of CD34 aptamers (Apts) for CD34+ orbital fibroblasts. The CD34 Apt-modified Toc-loaded MS (Toc-MS-CD34 Apt) were characterized by scanning electron microscopy (SEM), transmission electron microscopy (TEM), Fourier transform infrared spectroscopy (FT-IR), and agarose gel electrophoresis. The CCK-8 assay kit was used to examine cell viability. The EdU assay was used to assess cell proliferation. The scratch wound healing assay was applied to detect cell migration. Results The affinity of CD34 aptamers for CD34+ orbital fibroblasts was confirmed, demonstrating high specificity and binding strength. The Toc-MS-CD34 Apt exhibited size uniformity and successful aptamer conjugation. In vitro, studies showed that Toc-MS-CD34 Apt effectively inhibited the viability, proliferation and cell activation, ext

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Cells, CulturedFibroblastsAnimalsHumansMiceDisease Models, AnimalAntigens, CD34Microscopy, Electron, ScanningMicroscopy, Electron, TransmissionDrug Delivery Systems

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research